Literature DB >> 20872121

Clinical observation on the treatment of atrial fibrillation with amiodarone combined with Shenmai Injection (参麦注射液).

Min Deng1, Xiang-qian Sui, Shi-bing Zhu, Wei Ma, Ying Xu, Zhi-ming Chen.   

Abstract

OBJECTIVE: To observe the therapeutic efficacy and safety of amiodarone combined with Shenmai Injection (参麦注射液) on atrial fibrillation.
METHODS: A total of 351 patients with atrial fibrillation caused by cardiovascular diseases and idiopathic atrial fibrillation were assigned to amiodarone group (control group, 128 cases) and amiodarone combined with Shenmai Injection group (treatment group, 223 cases). The patients in the control group received intravenous injection of 150 mg amiodarone in 10 min, followed by intravenous drip infusion at 1 mg /min and 6 h later at 0.5 mg /min until 48 h or cardioversion. The patients in the treatment group received the same treatment of amiodarone, while in addition, they received an injection of Shenmai Injection of 100 mL simultaneously. Blood pressure, ventricular rate, and cardioversion were observed.
RESULTS: The total efficiency rate was 98% (control group) and 99% (treatment group) (P>0.05). The mean ventricular rate decreased 23% and 31% in the control group and the treatment group, respectively (P<0.05). The mean cardioversion time of the two groups was 570±211 min and 351±123 min, respectively (P<0.05). Only mild side effects were observed in both groups.
CONCLUSION: Compared with amiodarone, amiodarone combined with Shenmai Injection takes effect more quickly with low side effects on the treatment of atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20872121     DOI: 10.1007/s11655-010-0540-y

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  7 in total

1.  Amiodarone infusion in the treatment of acute atrial fibrillation or flutter: high versus low dose treatment.

Authors:  V Tuseth; H J Jaatun; K Dickstein
Journal:  Heart       Date:  2005-07       Impact factor: 5.994

2.  ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.

Authors:  Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; Jean-Yves Le Heuzey; G Neal Kay; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffery L Anderson; Elliott M Antman; Jonathan L Halperin; Sharon Ann Hunt; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; A John Camm; Veronica Dean; Jaap W Deckers; Catherine Despres; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; Joao Morais; Ady Osterspey; Juan Luis Tamargo; José Luis Zamorano
Journal:  Circulation       Date:  2006-08-15       Impact factor: 29.690

3.  A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned.

Authors:  Kunadian Vijayalakshmi; Victoria J Whittaker; Andrew Sutton; Philip Campbell; Robert A Wright; James A Hall; Alun A Harcombe; Nicholas J Linker; Michael J Stewart; Adrian Davies; Mark A de Belder
Journal:  Am Heart J       Date:  2006-04       Impact factor: 4.749

4.  Clinical outcome of patients with heart failure and preserved left ventricular function.

Authors:  Israel Gotsman; Donna Zwas; David Planer; Tanya Azaz-Livshits; Dan Admon; Chaim Lotan; Andre Keren
Journal:  Am J Med       Date:  2008-11       Impact factor: 4.965

5.  Intravenous amiodarone for cardioversion of recent-onset atrial fibrillation.

Authors:  Jacek Cybulski; Piotr Kułakowski; Andrzej Budaj; Henryk Danielewicz; Janusz Maciejewicz; Teresa Kawka-Urbanek; Leszek Ceremuzyński
Journal:  Clin Cardiol       Date:  2003-07       Impact factor: 2.882

Review 6.  Hybrid therapy of atrial fibrillation: algorithms and outcome.

Authors:  Sanjeev Saksena; Nandini Madan
Journal:  J Interv Card Electrophysiol       Date:  2003-10       Impact factor: 1.900

7.  Beta-blockers are effective in congestive heart failure patients with atrial fibrillation.

Authors:  Fanbo Meng; Tsutomu Yoshikawa; Akiyasu Baba; Kazunori Moritani; Masahiro Suzuki; Toru Satoh; Hitoshi Yokozuka; Akira Murayama; Satoshi Ogawa
Journal:  J Card Fail       Date:  2003-10       Impact factor: 5.712

  7 in total
  3 in total

Review 1.  Application of Traditional Chinese Medicine in Treatment of Atrial Fibrillation.

Authors:  Yan Dong; Jiangquan Liao; Kuiwu Yao; Wenrui Jiang; Jie Wang
Journal:  Evid Based Complement Alternat Med       Date:  2017-01-24       Impact factor: 2.629

2.  Comparison between the Effects of Oral and Intramuscular Administration of Shin'iseihaito (Xinyiqingfeitang) in a Streptococcus pyogenes-Induced Murine Sinusitis Model.

Authors:  Masaaki Minami; Toru Konishi; Hiroshi Takase; Toshiaki Makino
Journal:  Evid Based Complement Alternat Med       Date:  2018-05-02       Impact factor: 2.629

Review 3.  Mechanism-based targeting of cardiac arrhythmias by phytochemicals and medicinal herbs: A comprehensive review of preclinical and clinical evidence.

Authors:  Danesh Soltani; Bayan Azizi; Roja Rahimi; Azita H Talasaz; Hossein Rezaeizadeh; Ali Vasheghani-Farahani
Journal:  Front Cardiovasc Med       Date:  2022-09-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.